Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$4.36

-0.11 (-2.46%)

07:07
04/17/19
04/17
07:07
04/17/19
07:07

TherapeuticsMD announces commercial availability of BIJUVA in the U.S.

TherapeuticsMD announced the commercial availability of BIJUVA in the United States. BIJUVA is an FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. BIJUVA offers a balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical progesterone to reduce risks to the endometrium. As of April 19, 2019, three of the top ten commercial payers - Express Scripts, Anthem and Aetna - will be adjudicating BIJUVA in the commercial health insurance channel for the majority of their formulary designs. TherapeuticsMD plans to hold an Investor Day in New York on Monday, June 10, 2019 to highlight its commercial strategy for its product portfolio, including BIJUVA.

TXMD TherapeuticsMD
$4.36

-0.11 (-2.46%)

10/03/18
CANT
10/03/18
NO CHANGE
Target $27
CANT
Overweight
Cantor says TherapeuticsMD should have 'ample cash' through end of 2019
Cantor Fitzgerald analyst William Tanner believes some investors connected two of his prior comments about TherapeuticsMD disclosing ongoing labeling talks with the FDA regarding TX-001 and his foreseeing that the company would need to raise capital in the future and "jumped to" the conclusion that the company would raise capital after TX-001 approval, assuming that occurs. However, in an updated corporate presentation, the company noted a cash balance of $154.4M at the end of Q2 and Tanner projects cash of about $70M at the end of 2019 before the company becomes cash flow positive in the beginning of 2020. Tanner also noted that management has explained that their labeling talks disclosure was meant to take the topic off the table and prevent "awkward conversations" at Cantor's healthcare conference. The analyst, who now believes he was "dead wrong" in his assumption that the FDA talks disclosure may have been made to get "the stock moving," reiterates an Overweight rating and $27 price target on TherapeuticsMD shares.
12/11/18
CANT
12/11/18
NO CHANGE
Target $27
CANT
Overweight
FDA report highlights large opportunity for TherapeuticsMD, says Cantor
In a research note titled "Not Too Hot, Not Too Cold, Things Are Just Right at TXMD," Cantor Fitzgerald analyst Louise Chen keeps an Overweight rating on TherapeuticsMD with a $27 price target. The FDA released its "2018 Compounding Policy Priorities Plan," which underscores the "large and underappreciated" market opportunity for TherapeuticsMD' Bijuva, Chen tells investors in a research note. She points out that one of the priorities listed by the FDA includes: "Restricting Compounding of Drugs that are Essentially Copies of FDA-Approved Drugs." This is positive for Bijuva, says Chen. The analyst thinks the peak sales potential for the drug is $1B-plus.
01/07/19
CANT
01/07/19
NO CHANGE
Target $27
CANT
Overweight
TherapeuticsMD shares underappreciate three launches, says Cantor Fitzgerald
In a research note titled "I'm Vexxyed By TXMD's Stock Price," Cantor Fitzgerald analyst Louise Chen reaffirms an Overweight rating on TherapeuticsMD with a $27 price target. The execution of the Imvexxy, Bijuva and Annovera launches is underappreciated, Chen tells investors. She thinks peak sales could exceed "modest expectations for the three drugs that target large unmet needs." Discussions with two experienced OB-GYNs that have already prescribed Imvexxy and are excited to prescribe Bijuva and Annovera support a positive investment thesis on the stock, adds the analyst.
02/06/19
JEFF
02/06/19
DOWNGRADE
Target $5
JEFF
Hold
TherapeuticsMD assumed with a Hold from Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of TherapeuticsMD and downgraded his firm's rating to Hold from Buy. He also dropped the stock's price target to $5 from $15. While recognizing the company's large total addressable market, the analyst is cautious on the commercial success of TherapeuticsMD' assets due to a mature market and their "relatively low innovation." Further, he expects erosion of the hormone replacement therapy market for vasomotor symptoms with "innovative therapies" expected to come to market in the next five years.

TODAY'S FREE FLY STORIES

DLX

Deluxe

$46.49

0.355 (0.77%)

08:58
04/25/19
04/25
08:58
04/25/19
08:58
Earnings
Deluxe reports Q1 adjusted EPS $1.14, consensus $1.11 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

UPS

UPS

$114.39

0.79 (0.70%)

08:58
04/25/19
04/25
08:58
04/25/19
08:58
Hot Stocks
UPS says investments in networks starting to pay off »

Says: New automated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 21

    May

  • 05

    Jun

MMM

3M

$219.24

-0.28 (-0.13%)

08:57
04/25/19
04/25
08:57
04/25/19
08:57
Hot Stocks
3M sees FY19 Health Care organic local-currency sales growth 2%-4% »

Sees FY19 Safety &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

PYPL

PayPal

$107.18

0.27 (0.25%)

, EBAY

eBay

$38.51

1.85 (5.05%)

08:56
04/25/19
04/25
08:56
04/25/19
08:56
Recommendations
PayPal, eBay, Chipotle analyst commentary at Craig-Hallum »

PayPal price target…

PYPL

PayPal

$107.18

0.27 (0.25%)

EBAY

eBay

$38.51

1.85 (5.05%)

CMG

Chipotle

$710.00

7.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 11

    Jun

MMM

3M

$219.24

-0.28 (-0.13%)

08:56
04/25/19
04/25
08:56
04/25/19
08:56
Hot Stocks
3M sees FY19 CapEx $1.6B-$1.7B, share buybacks $2B-$4B »

Comments taken from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

WCN

Waste Connections

$89.28

0.01 (0.01%)

08:55
04/25/19
04/25
08:55
04/25/19
08:55
Earnings
Waste Connections sees Q2 revenue approximately $1.36B, consensus $1.35B »

Sees Q2 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 17

    May

  • 05

    Jun

FB

Facebook

$182.64

-1.13 (-0.61%)

, OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

08:55
04/25/19
04/25
08:55
04/25/19
08:55
Options
Notable open interest changes for April 25th »

Wednesday's total…

FB

Facebook

$182.64

-1.13 (-0.61%)

OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

TSLA

Tesla

$258.70

-5.15 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 07

    May

  • 10

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

08:55
04/25/19
04/25
08:55
04/25/19
08:55
General news
Treasury Action: yields cheapened a bit on the strong durables report »

Treasury Action: yields…

SHW

Sherwin-Williams

$457.85

-2.58 (-0.56%)

08:54
04/25/19
04/25
08:54
04/25/19
08:54
Downgrade
Sherwin-Williams rating change  »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBBPF

Prologis Property Mexico

$0.00

(0.00%)

08:54
04/25/19
04/25
08:54
04/25/19
08:54
Conference/Events
Prologis Property Mexico management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

NOW

ServiceNow

$242.41

-1.085 (-0.45%)

08:54
04/25/19
04/25
08:54
04/25/19
08:54
Recommendations
ServiceNow analyst commentary  »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

BIP

Brookfield Infrastructure

$41.62

-0.03 (-0.07%)

, BAM

Brookfield

$47.73

-0.51 (-1.06%)

08:53
04/25/19
04/25
08:53
04/25/19
08:53
Downgrade
Brookfield Infrastructure, Brookfield rating change  »

Brookfield Infrastructure…

BIP

Brookfield Infrastructure

$41.62

-0.03 (-0.07%)

BAM

Brookfield

$47.73

-0.51 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

APC

Anadarko

$71.41

7.29 (11.37%)

08:53
04/25/19
04/25
08:53
04/25/19
08:53
Downgrade
Anadarko rating change  »

Anadarko downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

ASPU

Aspen Group

$4.57

0.1 (2.24%)

08:52
04/25/19
04/25
08:52
04/25/19
08:52
Hot Stocks
Aspen Group announces accreditation for Family Nurse Practitioner degree »

Aspen Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENB

Enbridge

$37.82

0.145 (0.38%)

08:52
04/25/19
04/25
08:52
04/25/19
08:52
Downgrade
Enbridge rating change  »

Enbridge downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

GBNXF

Gibson Energy

$0.00

(0.00%)

08:51
04/25/19
04/25
08:51
04/25/19
08:51
Downgrade
Gibson Energy rating change  »

Gibson Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WWE

WWE

$98.47

-0.8 (-0.81%)

08:51
04/25/19
04/25
08:51
04/25/19
08:51
Hot Stocks
WWE reports Q1 WWE Network average paid subscribers up 2% »

WWE Network average paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    Jun

PRLB

Proto Labs

$117.21

3.29 (2.89%)

08:50
04/25/19
04/25
08:50
04/25/19
08:50
Earnings
Proto Labs sees Q2 EPS 66c-74c, consensus 76c »

Says prioritizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 15

    May

  • 16

    May

  • 28

    May

  • 28

    May

  • 05

    Jun

FB

Facebook

$182.64

-1.13 (-0.61%)

08:50
04/25/19
04/25
08:50
04/25/19
08:50
Recommendations
Facebook analyst commentary at Jefferies »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

08:50
04/25/19
04/25
08:50
04/25/19
08:50
General news
The 37k initial claims pop to 230k »

The 37k initial claims…

GOOGL

Alphabet Class A

$1,260.07

-10.53 (-0.83%)

, AMZN

Amazon.com

$1,900.72

-23.36 (-1.21%)

08:49
04/25/19
04/25
08:49
04/25/19
08:49
Recommendations
Alphabet Class A, Amazon.com analyst commentary  »

Alphabet price target…

GOOGL

Alphabet Class A

$1,260.07

-10.53 (-0.83%)

AMZN

Amazon.com

$1,900.72

-23.36 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

DHI

D.R. Horton

$46.67

0.275 (0.59%)

08:48
04/25/19
04/25
08:48
04/25/19
08:48
Earnings
D.R. Horton sees Q3 revenue $4.4B-$4.6B, consensus $4.75B »

Sees Q3 tax rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WWE

WWE

$98.47

-0.8 (-0.81%)

08:48
04/25/19
04/25
08:48
04/25/19
08:48
Earnings
WWE sees FY19 revenue of approx. $1B, consensus $1.03B »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    Jun

DPZ

Domino's Pizza

$282.93

12.68 (4.69%)

08:48
04/25/19
04/25
08:48
04/25/19
08:48
Recommendations
Domino's Pizza analyst commentary at Stephens »

Domino's Pizza price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 13

    Nov

TSLA

Tesla

$258.70

-5.15 (-1.95%)

08:47
04/25/19
04/25
08:47
04/25/19
08:47
Recommendations
Tesla analyst commentary at Jefferies »

Jefferies still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.